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Simulation modeling for stratified breast
cancer screening – a systematic review of
cost and quality of life assumptions
Matthias Arnold1,2,3
Abstract
Background: The economic evaluation of stratified breast cancer screening gains momentum, but produces also
very diverse results. Systematic reviews so far focused on modeling techniques and epidemiologic assumptions.
However, cost and utility parameters received only little attention. This systematic review assesses simulation
models for stratified breast cancer screening based on their cost and utility parameters in each phase of breast
cancer screening and care.
Methods: A literature review was conducted to compare economic evaluations with simulation models of
personalized breast cancer screening. Study quality was assessed using reporting guidelines. Cost and utility inputs
were extracted, standardized and structured using a care delivery framework. Studies were then clustered according
to their study aim and parameters were compared within the clusters.
Results: Eighteen studies were identified within three study clusters. Reporting quality was very diverse in all three
clusters. Only two studies in cluster 1, four studies in cluster 2 and one study in cluster 3 scored high in the quality
appraisal. In addition to the quality appraisal, this review assessed if the simulation models were consistent in
integrating all relevant phases of care, if utility parameters were consistent and methodological sound and if cost
were compatible and consistent in the actual parameters used for screening, diagnostic work up and treatment. Of
18 studies, only three studies did not show signs of potential bias.
Conclusion: This systematic review shows that a closer look into the cost and utility parameter can help to identify
potential bias. Future simulation models should focus on integrating all relevant phases of care, using
methodologically sound utility parameters and avoiding inconsistent cost parameters.
Background
Stratified breast screening aims at improving routine
screening by allowing a stratification between risk
groups. Stratified screening protocols could then be de-
veloped for high-risk and low-risk groups, and the bal-
ance between harmful and beneficial screening effects
could be recalibrated. Owing to the complex nature of
stratified screening programs and the massive cost im-
plications of randomized control trials, simulation mod-
eling is often the only method available or feasible for
economic evaluation. Health economic modeling aims to
support political decision-making, but its results are
often very diverse. Part of this diversity was found to be
related to a significant diversity in simulation techniques
and modeling approaches.
A recent review by Elkin et al. [1] compared simula-
tion models for stratified cancer interventions in 2011
with the aim of evaluating the risk stratification mechan-
ism, which they call the targeting mechanisms. They
found that the targeting mechanism is rarely included in
the decision analytical models, but influences the results
of cost-effectiveness studies substantially. Three years
later, Hatz et al. [2] provided an overview of health eco-
nomic assessments of personalized medicine. The au-
thors summarized how stratified approaches do not
necessarily lead to superior or inferior cost-effectiveness
compared with existing health care approaches. They
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also found that stratified screening was often more cost-
effective than stratified treatment but, overall, the vari-
ation in these studies was too substantial to reach a con-
clusion. Koleva-Kolarova et al. [3] reviewed simulation
models for population-based screening programs with
the aim of providing recommendations for future model-
ing endeavors. They assessed seven original models and
compared disease, population and intervention input pa-
rameters as well as modeling approach and outcomes.
They found that all of them predicted mortality reduc-
tion similar to randomized control trials. However, all of
them were also prone to bias, mainly due to a lack of ex-
ternal validation and due to “lack of systematic evalu-
ation of evidence to calibrate the input parameters” [4]
Owing to the large variety in personalization ap-
proaches, systematic reviews struggle with comparing
the specific stratification suggestions in the complex
continuum of care for breast cancer. Onega et al. [5] re-
alized that a conceptual model for the comparison of
stratified screening approaches was required and sug-
gested a framework based on the steps of care delivery
in stratified screening. Their framework described the
complete continuum of breast screening from risk as-
sessment to treatment and thus supported the assess-
ment of the care continuum in simulation models for
stratified screening. A systematic review focusing on the
integration of the phases of care and an assessment of
the cost and utility parameters used in each of the
phases thus might be helpful to further assess the simu-
lation models and evaluate if the underlying structural
assumptions are appropriate for the respective research
task.
This article describes such a systematic review and
presents an analysis of cost and utility parameters using
the Onega framework [5]. It assesses simulation models
for stratified breast cancer screening according to the in-
tegration of the phases of care delivery and illustrates
the variation in cost and utility parameters. By focusing
on their validity and their potential impact on results,
the importance of the respective phase of care for the
evaluation can be assessed and potential of bias can be
identified. Its aim is not to evaluate if stratified screening
is superior to routine screening, but to evaluate the eco-
nomic modeling approaches in this field.
Methods
Identifying research evidence
Stratification can be used in many areas of the breast
cancer patient pathway. Onega et al. [5] describe a
framework for stratified screening for breast cancer. We
used an adaptation of their framework to categorize
screening approaches into clusters focusing on risk as-
sessment, detection, diagnosis or breast cancer treat-
ment. This study focuses on approaches aiming at the
stratification of patient groups into risk levels and the
selection of the best screening strategy for each risk
group.
Study selection
The systematic literature search and the study selection
closely follow the guidelines of the PRISMA1 statement
[6]. The search strategy uses very broad descriptions for
stratification (or personalization), the screening for
breast cancer and also for studies including cost-
effectiveness. The search strategy uses MEDLINE2 data-
bases (also including the MEDLINE in-process and non-
indexed database), Embase database, Centre for Reviews
and Dissemination (CRD) databases (providing access to
DARE,3 NHS EED4 and HTA5 databases) and Econlit
databases. Search terms included “economic evaluation”,
“cost”, “benefits and harms”, “screening”, “breast cancer”,
“mammography”, “magnetic resonance imaging”, “per-
sonalized”, “risk-stratified” and “targeted”. Keywords and
synonyms were used in titles and abstracts. The search
string for each database can be found in Additional file 1:
supplementary material S1.
Since the terminology for simulation modeling is quite
diverse, no specific search term was used for the data-
base search. The search strategy thus was designed to
identify economic evaluations for personalized breast
cancer screening. In order to identify simulation models,
all identified economic evaluation were screened for the
population in their methodology. If simulated or hypo-
thetical populations were used, studies were identified as
simulation models. Studies of interest use comparative
simulation approaches and compare a variety of screen-
ing strategies, of which one needs to be routine mam-
mography screening and at least one needs to suggest a
stratified screening approach. They do not necessarily
need to reflect the current technology or current re-
search, but rather a fitting economic evaluation. The lit-
erature search results are then filtered using the
following inclusion criteria:
 Indication: Exclusively breast cancer
 Focus on new screening strategies, not on methods
to increase participation in existing strategies.
 Study type: Economic evaluation using simulation
modeling
 Evaluation approach: Comparison of risk-stratified
screening vs one-size-fits all screening
Exclusion criteria further filter out non-peer-reviewed
publications such as conference abstracts, commentaries
or study protocols, economic evaluations with updates,
economic evaluations that do not use a simulation ap-
proach or only review other simulations, economic eval-
uations that do not use utility values, studies focusing
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primarily on women with a specific socio-economic or
racial background, which are not comparable to other
studies. The literature search and evaluation were con-
ducted with the help of a second researcher and a review
protocol.
Literature appraisal and data extraction
Literature appraisal is based on an overview of reporting
guidelines [7] and challenges in the field of the economic
evaluation of personalized medicine as formulated by
Annemans et al. [8]. The overview [7] compares the
most commonly used quality appraisal tools for health
economic modeling [9–11]. The list extracted from this
review [11] adds additional elements [8]. Annemans et
al. [8] described ten challenges in the economic evalu-
ation of personalized medicine. While some of these
items are already adequately reflected in existing quality
appraisal tools, such as the importance of defining the
scope of the economic evaluation, others are not yet
completely addressed, for example the special import-
ance of incorporating both test and intervention specifi-
cations into the model. This quality appraisal helps to
establish a benchmark for a comparison of the study
quality for economic evaluations in personalized medi-
cine. A second researcher validated the quality appraisal.
Additional file 1: Supplementary material S2 includes
the checklist and explanation of the new items as well as
an illustration of the definition of good quality used for
the quality criteria.
Data extraction utilizes the framework in Fig. 1. The
framework uses four phases of care delivery in the pa-
tient’s pathway: risk assessment, screening, diagnostic
work up and treatment. In each of these phases, costs
can occur and quality of life can be affected. Data extrac-
tion focuses on the price parameters of technologies and
quality of life decrement used in each of these phases.
All monetary parameters are standardized to 2014 USD,
as the latest available year of purchasing power-parity-
based (PPP) exchange rates, and USD, as the most com-
mon currency. Quality of life decrements are reported as
percentages from the base value in order to normalize
utilities between studies using age-specific utility weights
and studies assuming perfect health independent of age.
Results
Search results
The search was run on 17th August 2017 and identified
2656 studies, 1251 from Embase, 944 from MEDLINE,
69 from Pre-MEDLINE, 379 from CRD and 5 from
Econlit and 8 additional references per hand search.
After removing duplicates, 1878 studies were assessed
for inclusion criteria. Of these, 771 studies did not focus
on breast cancer, 652 were not cost-effectiveness studies,
144 did not focus on screening, 107 studies did not as-
sess personalized approaches and 134 studies focused on
strategies for raising screening uptake or re-attendance.
70 studies remained and were assessed for eligibility. Of
these, 52 studies were excluded because they were con-
ference abstracts, outdated versions of newer publica-
tions, study protocols or comments on other papers, did
not describe results for risk groups, focused on co-
morbid study populations, did not apply health
economic models, did not measure quality of life with
utilities or only described models without implementing
them. In all, 18 studies fulfilled all criteria and were in-
cluded in this review. The PRISMA flow chart (Fig. 2) il-
lustrates the results of the literature search [6].
Personalization approaches
In 18 studies, three distinct clusters of stratification ap-
proaches were identified. One cluster focuses on strati-
fied screening in the general population, one focuses on
a pre-selected high-risk population and one evaluates
newly introduced risk assessment technologies. Table 1
provides an overview of suggested personalization ap-
proaches, risk factors used for stratification, the routine
strategy used for comparison, and effects on cost, util-
ities and the incremental cost-effectiveness ratio (ICER).
Cluster 1: Personalized screening in the general population
Studies in cluster 1 use risk factors describing moderate
risk to generate risk clusters. These risk factors are for
Fig. 1 Conceptual framework, adapted from Onega et al. [5]
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example familial risk, age, breast density, history of bi-
opsy and others. Schousboe et al. [12] and Vilaprinyo et
al. [13] use a relative risk of 1.5 for women with breast
cancer history in a first-degree relative or previous bi-
opsy and a spread of relative risk between 0.49 and 1.97
for the four categories of breast density. Sprague et al.
[14] and Tosteson et al. [15] use only breast density as a
risk factor. Sprague et al. [14] use the same relative risks
between 0.5 and 2.0 as Schousboe et al. [12] and Vilapri-
nyo et al. [13]. However, Tosteson et al. [15] use only
two categories of breast density with relative risks of
0.66 and 1.5; a much narrower risk spectrum. Stout et
al. [16] uses only breast density, however with a scale be-
tween 1.0 and 4.35 and the necessary adjustment of life-
time risk. Trentham-Dietz et al. [17] use undefined
relative risks between 1 and 4 and accordingly focus only
on women with normal or increased risk, but they do
not include women with relative risks below 1 as the
other studies.
Sprague et al. [14] evaluate supplemental ultrasonog-
raphy for women at moderate risk due to high breast
density. Tosteson et al. [15] evaluate digital mammog-
raphy compared to screen-film mammography for
women at moderate risk; a suggestion, which is already
outdated since most mammographic center are already
using digital mammography in the USA today [18]. The
other studies in cluster 1 suggest personalized screening
frequencies. Stout et al. [16] evaluate extending
screening from 50 to 40 years and increasing the screen-
ing frequency from biennial to annual for women with
high breast density. Schousboe et al. [12], Vilaprinyo et
al. [13] and Trentham-Dietz et al. [17], suggest triennial
mammography screening for 50-year-old women with
normal risk annual or biennial intervals for high-risk
women at 40 or 45 years.
Cluster 2: Screening women at high risk
In cluster 2, studies focus on identifying the right
screening technology for women already identified with
high risk of breast cancer. Most studies focus on
BRCA1/26 positive women, only three studies [19–21]
focus on other sources of high risk. Ahern et al. [19]
suggest alternating magnetic resonance imaging (MRI)
and mammography plus clinical breast examinations
(CBE) every year instead of screening only with MRI
every two years for women with lifetime risk over 25% at
25 years. Pataky, Ismail et al. [20] focus on women with
pre-selected high breast density. They evaluate using an-
nual mammography screening instead biennial for this
risk group.
The other studies in cluster 2 focus on BRCA1/2 posi-
tive women. Studies suggest stratification by adding MRI
for women at very high risk. Cott Chubiz et al. [22] sug-
gest alternating MRI and mammography every 6. The
other studies [23–26] propose annual screening using
Fig. 2 PRISMA flow chart
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Table 1 Personalization approaches, corresponding incremental cost and utility, ICER
Cluster Study,
study
country
Risk factors Personalization approach Proposed strategy for low/
high
risk group
Population and
comparative strategy
Effect or utility
increment
Cost increment in
USD
ICER (USD per
QALY)
Cluster 1:
screening in
general
population
[12], USA Age, breast density,
family history
Screening frequency Initial SFM at 40 years
Low: 3-to-4-year interval,
50–79 years
Average: biennial, 50–
79 years
Moderate: biennial, 40–
79 years
General population, 40–
79 years without screening
Not stated Not stated Not stated,
but <$100,000
/QALY
[16], USA Age, breast density Screening frequency Low: DM, biennial, 40–
79 years
Moderate: DM, annual, 40–
79 years
General population, 50–
79 years with biennial DM
0.03% higher utility 20.8% higher cost
($730)
$151,560
/QALY
[14], USA Breast density Screening technology Low: DM, biennial, 50–
79 years
Moderate: DM + US,
biennial, 50–79 years
General population, 50–
79 years with biennial DM
0.005% higher utility 12% higher cost
($370)
$246,000
/QALY
[17], USA Breast density, age,
other relative risks (1
to 4)
Screening frequency Low: DM, triennial, 50–
74 years,
Average: DM, biennial, 50–
74 years
Moderate: DM, annual, 50–
74 years
General population, 50–
74 years with biennial DM
Not stated Not stated Not stated,
but
<$100,000/
QALY
[15], USA Age, breast density Screening technology Low: SFM, annual, 40+
years
Moderate: DM, annual, 40+
years
General population, 40+
years with annual SFM
0.001% higher utility 6.0% higher cost
($139)
$69,575 /QALY
[13], USA Age, breast density,
family history (4 risk
groups)
Screening frequency Low: SFM, 4 years, 50–
69 years
Average: SFM, 4 years, 45–
74 years
Moderate: SFM, annual, 54–
74 years
General population, 50–
79 years with biennial SFM
3.8% higher utility 8.9% lower cost
(−$124)
Dominant
Cluster 2:
screening in high
risk population
[19],
Spain
Age, lifetime risk
(>25%)
Screening technology
and frequency
High: MRI / DM + CBE
alternation, annual, 30–
74 years
High risk population, 30–
74 years with biennial MRI
0.04% higher utility 3.8% higher cost
($1379)
$59,198 /QALY
[22], USA Age, BRCA1/2 Screening technology High: MRI / DM alternation,
biannual, 30+ years
BRCA population, 30+ years
with annual DM
0.2% higher utility 10.3% higher cost
($10,239)
$70,128 /QALY
(BRCA1)
$203,863/
QALY (BRCA2)
[21], USA Age, family history
(lifetime risk >15%)
Screening technology High: MRI, annual, 25–
50 years
High risk population, 25–
50 years with annual SFM
0.7% higher utility 281% higher cost
($11,598)
$115,983
/QALY
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Table 1 Personalization approaches, corresponding incremental cost and utility, ICER (Continued)
Cluster Study,
study
country
Risk factors Personalization approach Proposed strategy for low/
high
risk group
Population and
comparative strategy
Effect or utility
increment
Cost increment in
USD
ICER (USD per
QALY)
[23] BRCA1 Screening technology High: SFM +MRI annual,
30–49 years
BRCA population, 30–
49 years, with annual SFM
0.9% higher utility
in 30–39 and 1.8%
in 40–49
41% higher cost in
30–39 and 34% in
40–49
$15,525 /QALY
in 30–39 year
olds
$8987 /QALY
in 40–49 year
olds
[24], USA BRCA1 Screening technology High: SFM +MRI, annual,
25–70 years
High risk population, 25–
70 years with annual SFM
0.4% higher utility 10.6% higher cost
($9469)
$57,737 /QALY
[25], USA Age, BRCA1/2 Screening technology High: MRI, annual, 25–
29 years; MRI + SFM, annual,
30–49 years; SFM, annual,
50–75 years
High risk population, 25–
79 years with annual SFM
0.4% higher utility 90.2% higher cost
($3484)
$38,708 /QALY
[20],
Canada
High breast density Screening frequency High: SFM, annual, 50–
79 years
High risk population, 50–
79 years with biennial SFM
0.01% higher utility 42.5% higher cost
($579)
$413,571
/QALY
[26],
Canada
Age, BRCA1/2 Screening technology High: MRI + SFM, annual,
35–54 years
BRCA population, 25–
69 years with annual SFM
1.1% higher utility 21.2% higher cost
($10,626)
$45,725 /QALY
(BRCA1)
$107,832
/QALY
(BRCA2)
[27], USA Age, BRCA1/2,
lifetime risk (>20%)
Screening technology High: MRI + SFM at age
40 years
High risk population at
40 years with SFM
0.1% higher utility 34% higher cost
($589)
$21,189 /QALY
Cluster 3:
screening after risk
assessment
[31], USA Gail risk classification,
7SNP
Risk assessment plus
screening technology
Initial 7SNP testing
Low: SFM, annual, 40–
75 years
High: MRI, annual, 40–
75 years
General population, 40–
75 years with Gail testing
and the same screening
strategy
0.05% higher utility 7.6% higher cost
($503)
$158,318
/QALY
[29], USA BRCA1/2, family
history (lifetime risk
>10%)
Risk assessment plus
prophylactic surgery
plus screening
Initial BRCA1/2 testing
Low: no screening
High: risk reduction surgery;
MRI + SFM, annual, 30+
years
High risk population
(Ashkenazi), 30+ years with
family history based testing
0.1% higher utility 3.6% lower cost
(−$83)
Dominant
[28], UK Age, high risk (5-year
Gail risk >1.67%),
atypia
Risk assessment plus
chemoprevention plus
screening
Initial atypia testing at
40 years
Low: annual SFM, 40–
74 years
High: tamoxifen prevention,
40–74 years
High risk population, 40–
74 years with annual SFM
0.5% higher effect Higher costa (US
$1357)
US $6463/
QALY
SFM: screen-film mammography, DM: digital mammography, MRI: magnetic resonance imaging, CBE: clinical breast examination, BRCA1/2: breast cancer type 1/2 susceptibility protein
aThe authors do not assess the baseline strategy; they state zero cost for mammography screening. Thus, it is impossible to provide the relative cost increase.
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both technologies. Taneja et al. [27] use a single screen-
ing event instead of repeated screening.
Cluster 3: Additional risk assessment plus screening
In cluster 3, studies assess the introduction of additional
risk assessment to stratify women according to their risk.
The focus in these studies is on an earlier stage of the care
continuum compared to the studies in cluster 1 and 2.
Ozanne and Esserman [28] evaluate atypia testing to iden-
tify women for tamoxifen prevention. Manchanda et al. [29]
evaluate BRCA gene testing compared to an assessment of
family history in an Ashkenazi-Jewish population, who have
a very high risk of carrying BRCA positive genes [30]. Folse
et al. [31] compare the Gail tool [32] to 7SNP7 genetic test-
ing to select women for routine or intensive screening.
Quality assessment using quality appraisal checklist
Figure 3 presents the results of the quality assessment
with the help of the criteria list. When assessing the qual-
ity of simulation studies, the quality of the actual simula-
tion can only be assessed as far as all quality-relevant
items are reported in the main article, supplementary in-
formation or referenced articles and websites. In some
cases, the actual quality of the simulation model might be
higher, but cannot be assessed since the relevant items
were not reported in the article or referenced article.
Overall reporting quality is mixed
The criteria list includes 40 items with 40 positive an-
swers as the maximum possible score. Longer bars in
Fig. 3 indicate higher numbers of positive answers and
thus high quality, whereas shorter or missing bars indi-
cate lower quality. The bars use different colors to iden-
tify the quality categories. The complete checklist and
an explanation of the additional criteria can be accessed
in Additional file 1: supplementary material S2. Figure 3
shows that no article actually reaches 40: the highest
scores are 38 by Vilaprinyo et al. [13] and 36 by
Schousboe et al. [12]. Both studies supply extensive
supplementary material describing important assump-
tions and calculations in their simulation and thus
reach the highest transparency. The lowest scores are
22 [27] and 25 [19, 23]. All clusters have at least one
study with a quality of 30 or more positive answers,
but there is significant heterogeneity regarding report-
ing quality in all clusters.
Personalized screening imposes challenges on decision
analytic modeling
Two items should be explicitly highlighted, since they
reflect the challenges of reporting stratified screening
[8]. Annemans et al. [8] raised the issue that interven-
tions of personalized medicines always consist of a
Fig. 3 Quality appraisal, sum of positive answers
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combination of diagnostic and treatment with a degree
of uncertainty in both technologies, which is not always
adequately reflect in economic modeling. Their sugges-
tions for good quality were translated into questions
reflecting the context of stratified screening, which was
described detail in the Additional file 1: supplementary
material S2. Two of these questions are especially inter-
esting, these questions are: 1) Is the strategy in focus de-
scribed as a combination of risk assessment and
screening technology? 2) Are all key input parameters
incorporated into risk assessment and screening
technology?
Most studies do not adequately report or reflect how
risk assessment and intervention are combined.
All studies in cluster 1 and 3 explicitly mention the
risk stratification and suggest screening technologies for
each group. In cluster 2, risk assessment is routinely not
integrated into the models. Only Plevritis et al. [26] ex-
plicitly mention the risk assessment leading into the
stratified strategy. Regarding question 2), none of the
studies incorporates all key input parameters. Studies in
cluster 1 and 2 do not integrate risk assessment consist-
ently. Potential utility effects of knowing to be at higher
risk thus were not assessed. Screening is integrated as a
cost driver, but is not consistently allowed to have qual-
ity of life effects. Especially studies in cluster 3 often ex-
clude disutility from screening and diagnostic work up.
However, while the integration of all relevant phases of
care is desirable, there are reasons why certain elements
might be out of the scope for the individual economic
evaluation. The next paragraph discusses the scope and
assumptions in each cluster in greater depth.
Phases of care delivery
Table 2 shows the integration of the four phases of care
delivery as reflected by cost and utility parameter in each
specific phase. Accordingly, the gaps in the care delivery
are especially interesting.
Disutility from risk assessment is not adequately reflected
For studies in cluster 1, risk assessment can be imple-
mented without considerable cost implication, since all
personalization suggestions utilize risk factors that usu-
ally are already available after the first screening. Most
risk factors, such as family history with breast cancer,
previous biopsies and age at menarche or menopause
are readily collected at the first screening visit or are
available through the first screening, in the case of the
density of breast tissue. It is thus reasonable that risk as-
sessment may not introduce additional cost. However,
knowing to be at higher risk after risk assessment may
cause distress [33] and thus may affect quality of life.
Risk assessment is not necessarily perfect
Especially in cluster 2, these quality of life detriments
may be substantial since women are at very high risk
and thus anxiety and worry leading to quality of life
losses are higher. Plevritis et al. [26], though not imple-
menting it as a standard, acknowledge this effect in the
assessment of BRCA positive women by testing potential
utility losses after risk assessment and the effects of re-
assurance through negative screening in a sensitivity
analysis.8 Excluding the risk assessment can limit the
generalizability of results. The assumption underlying
these studies is that at-risk women can be perfectly iden-
tified through established systems. However, genetic test-
ing or risk assessment based on risk calculation does not
always deliver perfect information [34, 35].
Screening can affect quality of life
Most studies in clusters 1 and 2 include short-term util-
ity loss from mammography screening. Only six studies
[12, 13, 15, 19, 23, 27] do not integrate utility loss or at
least test it in sensitivity analysis. Among the studies not
integrating utility losses, those suggesting adjusted
screening frequencies [12, 13, 19] may overestimate the
utility gains from more intensive screening.
Cost and disutility from diagnostic work up are most
often included
Diagnostic work up, most importantly invasive proce-
dures, are accompanied with temporal utility loss [36].
While mostly included, five studies [15, 19, 23, 27, 31]
do not integrate these losses and thus overestimate the
quality of life improvements from intensified screening.
Two studies in cluster 3 do not include screening and
diagnostic work up at all, despite using mammography
screening to detect breast cancers [28, 29]. They assume
that screening and diagnostic work up stay unaffected
and thus are not integral to their evaluation.
Data sources of cost parameters and perspectives
Table 2 also shows the data sources of cost parameters
and the perspective of the economic evaluation. When
cost parameters are based on national tariffs, they repre-
sent what the service provider charges from the national
cost carrier for providing the health service. This is often
the case in studies, which choose the perspective of na-
tional cost carriers. It might however not represent the
actual resource consumption experienced at societal
level. Instead of using payments, authors can use infor-
mation from cost-of-illness studies, reflecting the actual
cost occurred for service delivery. If used consistently,
both types of information lead to consistent decision-
making [37, 38], but special attention must be paid if
cost parameters are mixed from both types of sources.
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The three studies from the Cancer Intervention and
Surveillance Modeling Network (CISNET) [14, 16, 17]
use the same cost parameters. They use Medicare reim-
bursement charges and treatment cost estimates from an
excess costing study [39]. The latter does, however, use
prices from the same Medicare reimbursement cata-
logue, which is why they still represent the cost occurred
at national payer (Medicare).
Cott Chubiz et al. [22] and Lee et al. [24] mix charges
from the physician fee schedule for screening and biopsy
Table 2 Phases of care delivery and input parameters
Cluster Study Study perspective Risk
assessment
Detection (screening) Diagnostic work up Treatment
Cost Utility Cost Utility Cost Utility Cost Utility
Screening in general
population
[12] Provider/Payer ✓
Charges
✓
Charges
✓
Assumption
✓
Charges
✓
EQ-5D S
[16] Provider/Payer ✓
Charges
✓ TTO
expert
✓
Charges
✓
TTO expert
✓
Cost
✓
EQ-5D A
[14] Provider/Payer ✓
Charges
✓ TTO
expert
✓
Charges
✓ TTO
expert
✓
Cost
✓
EQ-5D A
[17] Not mentioned ✓
Charges
✓ TTO
expert
✓
Charges
✓ TTO
expert
✓
Cost
✓
EQ-5D A
[15] Societal and Provider/
Payer
✓
Charges
✓
Charges
✓
Charges
✓
EQ-5D A
[13] Provider/Payer ✓
Cost
✓
Cost
✓
Assumption
✓
Cost
✓
EQ-5D S
Screening in high risk
population
[19] Societal ✓
Charges
✓
Charges
✓
Charges
✓
Expert VAS
[22] Not mentioned ✓
Charges
✓
Not
described
✓
Charges
✓
Not
described
✓
Cost
✓
Not
described
[21] Provider/Payer ✓
Charges
✓
Not
described
✓
Charges
✓
Not
described
✓
Charges
✓
Not
described
[23] Provider/Payer ✓
Cost
✓
Cost
✓
Cost
✓
TTO patient
[24] Societal ✓
Charges
✓
Assumption
✓
Charges
✓
Assumption
✓
Cost
✓
EQ-5D A
[25] Provider/Payer ✓
Charges
✓
Assumption
✓
Charges
✓
VAS - SG
✓
Charges
✓
SG patient
[20] Provider/Payer ✓
Cost
✓
Assumption
✓
Cost
✓
VAS - SG
✓
Charges
✓
SG patient
[26] Societal ✓
Charges
✓
Assumption
✓
Charges
✓
Assumption
✓
Charges
✓
Assumption
[27] Provider/Payer ✓
Charges
✓
Charges
✓
Charges
✓
Assumption
Screening after risk
assessment
[31] Not mentioned ✓
Charges
✓
Charges
✓
Charges
✓
Charges
✓
EQ-5D A
[29] Not mentioned ✓
Cost
✓
Charges
✓
Charges
✓
Assumption
[28] Not mentioned ✓
Cost
✓
Cost
✓
Mix
✓ indicates studies that included the respective phase in their cost or utility framework
EQ-5D S refers EQ-5D health utilities using an English tariff [56] in a Swedish population [49]
TTO expert describe expert interviews using a time-trade-off method to extract health utilities [36]
EQ-5D A refers EQ-5D health utilities using a tariff based on assumptions for disutility from breast cancer and a time-trade-off estimate for healthy individuals in
an American population [50]
Expert VAS refers to visual analogue scale health utilities based on expert interviews [36]
VAS – SG refers to VAS health utilities in American women enrolled in mammography screening [57] which were transformed to represent standard
gamble values
TTO patients refers to time-trade-off study with patients in the UK [58]
SG patient refers to standard gamble health utilities estimated in an American patient population [59]
Mix describes that the authors used a mean value of a selection of time-trade-off, standard gamble and rating scales [28]
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cost estimation and add treatment expenditure from an
excess costing study [40] with treatment cost for older
women from a micro-costing study [41]. While both
studies reference the same sources, the actual direct
treatment cost are significantly different even after ac-
counting for price inflation between the price years.
Pataky, Ismail et al. [20] combine screening and diag-
nostic work up cost from the screening program [42]
and treatment charges from the medical services fee
schedule [43]. Manchanda et al. [29] use mostly national
tariffs from the National Institute for Health and Care
Excellence (NICE), but in absence of a NICE unit price
for genetic testing and counselling, they use cost esti-
mates from trial data [44].
While most studies use the payer/provider perspec-
tive, five studies do not explicitly mention which per-
spective they chose [17, 22, 28, 29, 31]. Four studies
explicitly stated that they use the societal perspective
[15, 19, 24, 26]; all but one [26] adequately include
cost occurring at patient level.
Screening parameters and diagnostic work up
Table 3 presents the input parameters for screening and
diagnostic work up phases. In cluster 1, screening prices
are very homogenous (see Additional file 1: supplemen-
tary material S4 for details). The actual price for a life-
time of screening shows a considerable range, but the
difference between lower and higher risk women is in
almost all studies between US $2000 and US $2500.
Vilaprinyo et al. [13] use a very different price range
for Spain. For diagnostic work up, the CISNET stud-
ies [14, 16, 17] use the same cost and utility
parameters.
Personalized screening women with lifetime risk between
15% and 25% costs between US $1276 and US $20,550
In cluster 2, the screening proposals show bigger vari-
ation in screening cost. The three studies focusing on
women between 15% and 25% lifetime risk [19–21]
propose screening strategies for US $1276 (annual mam-
mography), US $19,382 (for annual screening with alter-
nating MRI and mammography) or US $20,550 (for
annual MRI). One study [19] does not include utility loss
from screening and diagnostic work up, while the other
studies include at least utility losses from diagnostic
work up.
BRCA gene carriers cost between US $7659 and US
$31,635 depending on MRI cost and intensity
In cluster 2, proposals for BRCA positive women
[22, 24–26] vary in lifetime screening cost between
US $5945and US $31,635. One strategy with very
high screening frequency but low cost [25] suggests
23 MRI screening events and 43 screening events
from the age of 25 to 75 in a woman’s lifetime for
US $7659. Pataky, Armstrong et al. [25] use signifi-
cantly cheaper MRI cost, which explains why lifetime
screening cost are comparatively low. For the other
strategies, the actual prices are very similar (Add-
itional file 1: supplementary material section S4);
cost differences thus derive from the screening mo-
dality. Cott Chubiz et al. [22] suggest annual alterna-
tion of MRI and mammography from 50 years on.
At the age of 70, each women thus would undergo
20 MRI and 20 mammography screenings for US
$14,060. Two studies [23, 26] combine MRI and
mammography every year, but limit screening to 35
to 54 years. In total, this sums up to 19 MRI and 19
mammography screenings for US $17,613. The
remaining cost differences comes from slightly more
expensive MRI screening (US $856 vs US $506).
Norman et al. [23] suggest a very similar combined
screening strategy for the UK, which has significantly
cheaper screening prices, which explains also the sig-
nificantly cheaper lifetime screening cost of US
$5945. The most expensive strategy [24] consists of
annual MRI and mammography from the age of 25
to 70, summing up to 45 MRI and 45 mammography
screenings. For the diagnostic work up, three of the
studies use very similar prices. Only one study [25]
uses significantly lower price compared to the other
studies, reflecting the price levels in the Canadian
health system. The consistent use of low prices leads
to more affordable screening and diagnostic work
up. In the Canadian health system due to the lower
screening prices compared to American health sys-
tem, even very intensive MRI screening can be cost-
effective.
Additional risk assessments require more research
In cluster 3, initial risk assessment leads into risk stratifi-
cation. Risk assessment costs from US $101 (for BRCA
testing in Ashkenazi-Jewish women) over US $272 (for
atypia testing using random fine-needle aspiration) to
US $3677 (for 7SNP testing). Folse et al. [31] suggest an-
nual MRI for high-risk women after 7SNP testing, which
costs US $24,325 for 35 screenings between 30 and
70 years. In contrast, Manchanda et al. [29] estimate that
35 screening events of MRI and mammography cost
only US $14,800 for high-risk women after BRCA test-
ing. The cost difference derives from price differences in
MRI screening, which is only US $318 [29] compared to
US $695 [31]. Owing to the price assumptions of MRI
screening, the actual screening cost in Manchanda et al.
[29] are higher. Ozanne and Esserman [28] suggest tam-
oxifen prevention (US $24,140 for women between 40
and 70) for high risk and mammography screening for
low-risk women; however, they do not report the actual
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Table 3 Screening and diagnostic work up cost and utility parameters
Cluster Study Cost of
screening in
2014 USD
over lifetime
(in risk group)
Utility loss from
screening (%)
Additional imaging Biopsy
Probability of false
positive
Diagnostic recall in 2014
USD
Probability of
biopsy
Diagnostic biopsy in 2014
USD
Utility loss from work
up
Screening in general
population
[12] Low: $812
Moderate:
$3822
Not included They combine imaging and biopsy 3.1–9.1% $360 0–0.013 for 1 year
[16] Low:$ 2652
Moderate:
$5304
0.6% for 1 week n.a. $131 n.a. $863 10.5% for 5 weeks
[14] Low: $1972
Moderate:
$3393
0.6% for 1 week n.a. $135 n.a. $889 10.5% for 5 weeks
[17] Low: $1104
Average:
$1656
Moderate:
$3312
0.6% for 1 week n.a. $141.42 10.6% $1354–$1442 depending on
age
10.5% for 5 weeks
[15] Low: $2840
Moderate:
$4480
Not included 6.3–6.8%a SFM: $65
DM: $95
US: $58
6.3–6.8%a FNA: $377
CNB: $290–$933
Surgical: $1402–$1700
Not included
[13] Lowe: $247
Average: $377
Moderate:
$1248
Not included 2.8% SFM: $34
US: $442
0.26% $701 0.013 for 1 year
Screening in high risk
population
[19] $19,382 Not included 13.5% DM DM: $166 2.95% $636 Not included
[22] $14,060 DM: 0–10% for
1 week
MRI: 0–20% for
1 week
5.59% SFM + US b DM: $125
US: $83
0.52% CNB: $795–$1420
Surgical: $2397–$2499
0–30% for 2 weeks
[21] $20,550 1% for 1 year They combine
imaging and biopsy
5.4–10.8% $503 11% for 1 year
[23] $5945 Not included n.a. MRI: $258
US: $56
n.a. Biopsy: $276 Not included
[24] $31,635 SFM: 0–10% for
1 week
MRI: 0–20% for
1 week
3–8% SFM: $68
US: $53
0.3–0.8% CNB: $662–$1302
Surgical: $1550–$1646
0–30% for 2 weeks
[25] $7659 0% They combine
imaging and biopsy
n.a. $135 1.3% for 1 year
[20] $1276 0% They combine
imaging and biopsy
4.3–8.2% $125 0.6% for 1 year
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Table 3 Screening and diagnostic work up cost and utility parameters (Continued)
Cluster Study Cost of
screening in
2014 USD
over lifetime
(in risk group)
Utility loss from
screening (%)
Additional imaging Biopsy
Probability of false
positive
Diagnostic recall in 2014
USD
Probability of
biopsy
Diagnostic biopsy in 2014
USD
Utility loss from work
up
[26] $17,613 0–5% for 1 year 7% SFM + US SFM: $64
US: $58
MRI: $649
1.6% FNA: $382
CNB: $432–$792
Surgical: $1040–$1383
0–17% for 1 week
[27] $927 Not included 19% SFM + US SFM: $64
US: $58
MRI: $649
7.2% FNA: $382
CNB: $432–$792
Surgical: $1040
Not included
Screening after risk
assessment
[31] Test: $916
Low: $2765
High: $24,325
Not included 23% SFM + US $251 9.6% n.a. Not included
[29] Test: $101
Low risk: $0
High: $14,800
Not included Not included
[28] Test: $276
Low: n.a.
High: $24,140
Not included Not included
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cost of mammography screening. It is thus unclear if all
relevant cost are included.
False positive results mostly result in quality of life
detriments, but extent varies
Screening produces false positive results, which may
affect quality of life. While most studies analyze util-
ity losses from diagnostic work up, seven studies ex-
clude these effects and thus overestimate quality of
life from screening [15, 19, 23, 27–29, 31]. Ozanne
and Esserman [28] propose tamoxifen prevention as a
screening replacement and underestimate potential
quality of life losses associated with false positive
screening results. The actual effect on quality of life
varies in its extent and duration. In general, studies
reflect a short-term (1 to 5 weeks) significant impact
(10 to 30%) on quality of life. Over the course of a
complete year, quality of life is reduced by 0.33% to
1.15%, which is also in line with the other studies
using a yearly average. Only Moore et al. [21] assume
a significant long-term effect of 11% over a complete
year, which is higher than suggested by other studies
[36, 45, 46]. Closer inspection of the health utilities
however reveals that there is currently no methodo-
logically sound set of health utilities for screening
and diagnostic work up. Utilities implemented so far
are either assumption-based or from expert inter-
views. This might explain why most studies restrain
from implementing disutility from screening and diag-
nostic work up, despite there being some evidence
that quality of life might be affected. The uncertainty
of this parameter, however, is sometimes reflected in
the sensitivity analyses. We did find that three studies
tested disutility from screening [14, 21, 26]. Disutility
from diagnostic work up was tested more frequently
in cluster 1 (all but two studies [15, 17]) and cluster
2 (all but three studies [19, 23, 27]).
Treatment parameters
Table 4 shows cost of and utility loss from treatment as
well as the probabilities of treatment. The following sec-
tion discusses four noteworthy differences in the as-
sumptions utilized for the treatment phase.
Studies vary in the treatment of in situ cancers
While most studies include the treatment of in situ
cancers and the corresponding utility loss, six studies
do not include in situ cancer treatment [13, 19, 21,
23, 26, 29]. More intensified screening, especially MRI
screening, usually to a higher identification of in situ
cancers [47, 48].
Treatment costs are not consistent through the course of
the disease
Almost all studies use stage-specific cost of treatment,
only two studies [23, 29] do not distinguish stage-
specific treatment cost, which reduces the benefit of
early detection. Among the rest, four studies stand out
which use lower treatment cost for metastatic disease
than regional disease [15, 22, 24, 25]. Naturally, earlier
diagnosis is less beneficial under this assumption. Simi-
larly, another study uses lower end of life cost for meta-
static patients than for regional cancer patients [15],
which also reduces potential savings from early detection
and contradicts the other studies.
While most studies do not use end of life cost for
other causes of death, Cott Chubiz et al. [22] integrate
these alternative end of life costs. In their study, non-
breast cancer mortality is more expensive than mortality
from ductal carcinoma in situ (DCIS), local or regional
carcinoma. Only distant carcinoma are more expensive
than dying from other causes. The assumption that
women dying from DCIS is cheaper than women dying
from other causes is not plausible. DCIS are by defin-
ition nonlethal; DCIS mortality thus can only consist of
the cost of dying from other causes in women with
DCIS. The question arises why women with DCIS are
being treated differently than women without DCIS in
their last life year.
Utility parameters for treatment are based on one of two
EQ-5D sets or assumptions
One of two sources are routinely being used for the
health utility in cluster 1: A Swedish study [49], which
uses an English time-trade-off (TTO) tariff on a Swedish
population. Or an EQ-5D estimate from Stout et al. [50],
which applies a tariff based partly on assumptions for
breast cancer utility loss and an American (TTO) tariff
[51] for healthy individuals to the Medical Expenditure
Panel Survey [15, 50]. There are significant differences
in these EQ-5D estimates. For example, the Swedish
study [49] estimates 25% utility loss for metastatic dis-
ease, while the Stout utility set [14–16, 22, 24] uses 40%
utility loss.
On one hand, there is the question if transferring the
Lidgren tariff to the American setting is valid. On the
other hand, the Stout utility set uses expert interviews
for the disutility from screening and diagnostic work up,
which certainly requires additional validation. While
both EQ-5D sets have their pitfalls, they are methodo-
logical more robust than what is being used in cluster 2
and 3. Only one study in cluster 2 and cluster 3 use
similar EQ-5D sets, while the other studies rely com-
pletely on assumptions, survey from very small samples,
mixed sources or expert opinions.
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Table 4 Parameters for direct cost of cancer treatment per stage
Cluster Study Is over-
diagnosis
assessed?
Lifetime
risk in
normal
risk
Relative risk
(risk factor)
Initial treatment cost per stage in USD Utility loss per stage (%) End of life cost in USD
In situ Early invasive Meta-
static
In situ Invasive Meta-
static
Other
causes of
death
Early
invasive
Metastatic
Screening in
general population
[12] Yes 12.35%a 0.49–1.97
(BD)
0.9–1.5 (FH)
0.9–1.5 (Biop)
$8088 Local: $10,650; regional:
$20,101
$31,096 10% Local: 15%; regional:
25%
25% Not used Local:
$28,824
Regional:
$34,119
US
$47,776
[16] Not
mentioned
12.35%a 1–4.35 (BD) $12,660 Local: $12,660; regional:
23,934
$36,964 10% Local: 10%; regional:
25%
40% Not used Local:
$34,265
Regional:
$40,558
US
$56,888
[14] Not
mentioned
12.35%a 0.49–2.00
(BD)
$13,042 Local: $13,042; regional:
$13,042
$28,239 10% Local: 10%; regional:
25%
40% Not used Local: $
35,300
Regional:
$41,784
US
$58,607
[17] Yes 12.35%a 1–4 $13,696 Local: $13,696; regional:
$25,894
$39,991 10% Local: 10%; regional:
25%
40% Not used Local: $
35,070
Regional:
$ 43,879
US
$61,545
[15] Not
mentioned
12.35%a 0.66–1.5 (BD) $11,972 Local: $15,239; regional:
$17,260
$ 0c 10% Local: 10%; regional
25%
40% Not used Local:
$16,939
Regional:
$23,003
US
$21,089
[13] Yes 5.8% by
75 years
0.49–1.97
(BD)
0.9–1.5 (FH)
0.9–1.5 (Biop)
Not
included
Stage 1: $14,763; Stage 2:
$21,665: Stage 3: $25,686
$42,115 Not
included
Local: 10%; regional:
25%
25% Not used They included end of
life cost in the
treatment of
metastatic cancers
Screening in high
risk population
[19] Not
mentioned
13% Above 25%
lifetime risk
Not
included
Local: $12,661; regional:
$23,937
$39,970 Not
included
13–26% n.a. Not used Local:
$34,269
Regional:
$40,564
US
$56,896
[22] Not
mentioned
65% by 70 years (BRCA) US
$8821
Local: $11,360; regional:
$21,985
$15,162 10% Local: 10%; regional:
25%
40% $42,222 Local:
$36,470
Regional:
$38,326
$43,705
[21] Not
mentioned
>15% (HIGH) Not
included
Local therapy: $11,160 b $
22,164
Not included Breast cancer: 5%
Node positive: 20%
False neg. Node pos.: 34%
[23] Not
mentioned
41% by 50 years (BRCA1) Not
included
Without stages: $7508 Not
included
Without stages: $7508 Not included
[24] Not
mentioned
65% by 70 years (BRCA) US
$20,585
Local: $35,073; regional:
$58,165
$45,502 10% Local: 10%; regional:
25%
40% Not used Local:
US31,530
Regional:
$31,530
$37,865
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Table 4 Parameters for direct cost of cancer treatment per stage (Continued)
Cluster Study Is over-
diagnosis
assessed?
Lifetime
risk in
normal
risk
Relative risk
(risk factor)
Initial treatment cost per stage in USD Utility loss per stage (%) End of life cost in USD
In situ Early invasive Meta-
static
In situ Invasive Meta-
static
Other
causes of
death
Early
invasive
Metastatic
[25] Not
mentioned
42.7% by 65 years
(BRCA)
US
$2481
Local: $7919; regional:
$17,091
$11,324 3.5% Local: 14%; regional:
32.5%
62% Not used Local:
$19,329
Regional:
19,329
$19,329
[20] Not
mentioned
26.6% from 50 to
79 years (BIRAD)
US
$3116
Stage 1: $4145; stage 2:
$6748; stage 3: $8274
$16,443 3.5% Stage 1: 9%; Stage 2:
25%; Stage 3: 49%
55% Not used Not used / included
in overall treatment
cost
[26] Yes 45–65% by 70 years
(BRCA)
Not
included
n.a. $34,619 Not
included
17% 41% Not used
[27] Not
mentioned
20% 40% (BRCA) $24,429 Local: $24,429; regional:
$45,000
$34,619 n.a. 17% 41% Not used
Screening after risk
assessment
[31] Not
mentioned
12.35%a 1.07–1.26
(7SNP)
$7734; Stage 1: $13,889; Stage 2:
$23,183; Stage 3: $18,449
$41,387 0% Local: 10%; regional:
25%
40% Not used Stage 1:
$40,229
Stage 2:
$45,683
Stage 3:
$51,733
$66,429
[29] Not
mentioned
13% 4.08 (BRCA) Not
included
Without stages: $19,533 Not
included
29% 35% Not used Terminal cancer care:
$18,579
[28] Not
mentioned
12.35%a 3.0 (atypia) $9271 Local: $13,809 $14,276 13% 32% 62% Not used
aThe study is based on SEER incidence data [60], lifetime risk from 0 to 95 years
bThe study identifies local and systemic therapy. The assumption here is that metastatic patients receive local therapy and systemic therapy
cThe authors only use ongoing treatment cost
BD = breast density, FH = family history in first degree relative, Biop = previous biopsy, BCRA = gene mutation BCRA1 or 2, HIGH = unspecified high risk population; atypia = atypical hyperplasia found
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Treatment parameters are not routinely included in
sensitivity analyses
The cost parameters for treatment show substantial vari-
ation in the studies and thus the question arises if
changes in the cost parameter affect results. Ten studies
check variations in the cost parameter with sensitivity
analyses. However, none of those studies with sensitivity
analyses report that results were sensitive to changes in
treatment cost. Surprisingly, the three studies with the
highest lifetime risk do not check robustness when treat-
ment costs changed [22, 24, 26]. In these studies, in
which the likelihood of breast cancer is very high, the
cost of treatment could be a sensitive parameter. Screen-
ing prices are subject to sensitivity analyses in 14 studies,
and seven studies find results to be sensitive to changes
in screening prices, mostly referring to changes in the
price of MRI screening. The simulation of Manchanda
et al. [29] is the only one suggesting MRI screening,
without checking if the MRI price is a sensitive param-
eter. Most of these nine studies also change utility losses
from breast cancer; only two studies vary only the cost
parameters. Only one study finds that results are sensi-
tive to changes in utility changes [31]. Additional file 1:
Supplementary Table S6 provides a full overview of the
sensitivity analyses.
Discussion
This systematic review assessed 18 simulation models
for stratified approaches towards breast cancer screen-
ing. The approaches were clustered into three distinct
groups. 1) A group of studies suggesting stratification of
the general population, 2) a group of studies stratifying a
pre-selected high-risk population and 3) a group of stud-
ies suggesting new risk assessment technologies. Quality
appraisal was conducted using modified quality checklist
[7]. Reporting quality was very diverse with only two
studies [12, 13] in cluster 1 fulfilling 30 or more items of
the 40-item quality checklist. In cluster 2 and 3, four
studies [22, 24–26] and one study [31] had good quality
using the same criteria of 30 items. In addition to the
quality appraisal, simulation models were assessed for
consistency in integrating all relevant phases of care,
methodological sound utility parameters and the
consistency and appropriateness of cost input
parameters.
Gaps in the phases of care
Studies often do not integrate in situ cancers into their
models. Intensified screening often leads to higher detec-
tion of in situ carcinoma [52], especially if screened with
MRI [47, 48]. In situ carcinoma may or may not pro-
gress to invasive cancers. Schiller-Fruhwirth et al. [53]
identified the uncertainty about the biological relation
between in situ and invasive cancers to be the root of
the differences in modeling. However, treatment guidelines
usually recommend treatment of in situ cancers [54, 55].
With increased screening, diagnosis of in situ carcinoma
will increase and thus treatment of in situ cancers should
be included in the economic evaluation. Simulation models
thus do not capture all screening effects if in situ cancers
are not integrated [13, 19, 21, 23, 26, 29].
The simulation models often do not integrate all rele-
vant phases of care. Especially potential utility losses
from screening and diagnostic work up are not routinely
integrated. Only eleven studies integrate these utility
losses, but nine studies do not address them [12, 13, 15,
19, 23, 27–29, 31]. This analysis has shown that there
are currently no methodologically sound utility weights
for screening and biopsy, but there is evidence that qual-
ity of life is affected at least in the short-term in screen-
ing and more importantly in diagnostic work up. By not
including these utility decrements, the assumption of
zero utility loss is automatically used, which does not re-
flect the underlying uncertainty and potentially biases
the assessment of screening effects.
Utility parameters are assumption-based, used out of
their original context, or methodological not sound
Among the studies suggesting stratified screening for the
general population, there are noteworthy differences.
Two studies use EQ-5D utility estimates from a Swedish
population for an American health care setting, which
might raise the question if the Swedish estimates can be
transferred to the American population. The utility esti-
mates are significantly different compared to an Ameri-
can EQ-5D tariff based on similar methods. The lack of
precise utility parameters was identified as a potential
bias in many simulation studies [53]. Three of the stud-
ies [14, 16, 17] with lower scores in the quality appraisal
utilized more than one simulation model. This research
design produces higher robustness, since up to five
simulation models evaluate the same strategy. On the
downside though, the adaption of these models to the
new research question is not reported in sufficient detail,
which leads to lower reporting quality. However, all
three studies integrate all relevant phases of care and
use consistent cost and utility parameter, which is why
these models produce currently the best available evi-
dence for stratification screening in the general popula-
tion. In the other clusters, only two studies [24, 31] use
the American EQ-5D utility set for treatment effects on
quality of life. The other studies use either sets based on
assumption or on surveys from very small samples.
Inconsistencies in cost parameters
On the side of the cost assumptions, four studies use in-
consistent treatment parameters. Four studies use pa-
rameters for the treatment of metastatic disease, which
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is substantially cheaper than treatment of earlier cancer
[15, 22, 25, 26]. Two studies do not distinguish the spe-
cific cancer stage in treatment [23, 29] and one study
has lower end of life cost for more advanced cancers
[15]. These sets of parameters appear implausible and
contradict the intuition from the other simulation
models. With these inconsistencies in the cost parame-
ters, cost savings from earlier detection and treatment is
reduced and the cost impact of screening is potentially
biased.
This systematic review has some limitations. The
focus on evaluations comparing stratified against rou-
tine screening lead to a very low number of studies,
which does not necessarily represent the complete
spectrum of stratified approaches. By using this re-
striction, many economic evaluations in the field of
personalized screening may not have been part of this
study. However, this systematic review assesses the in-
tegration of the care delivery framework. The integra-
tion is necessarily required for evaluations who
compare risk-adapted screening against routine
screening, but might not necessarily be required for
studies focusing only on stratified strategies. An as-
sessment based on the care delivery framework thus
would not be fair judgement for these evaluations,
which is why the studies in focus here are only those
who compare personalized screening against routine
screening.
The quality appraisal uses sum scores of positive an-
swers. Sum-scores might create a misleading picture of
the importance of each of the underlying questions,
since they put equal weight on every question. This is in
general not the intention of the quality checklists; how-
ever, this assumption allows getting a first overview be-
fore illustrating selected items in detail. In addition,
quality appraisal can only assess methods and parame-
ters if they are reported in the article, which might not
always represent the true effort put into the simulation
model.
This review compares cost parameters across countries
using international purchasing power parities. Although
this method eliminates currency and purchasing power
differences, it does not take into account the health sys-
tem related differences in national tariffs. In the process
of standardizing parameters, additional calculations were
required to enable comparison. Whenever approxima-
tions were calculated, it was indicated in the text or in a
footnote.
While essential steps of this systematic review, such as
the literature search and quality appraisal, used two re-
searchers, a single reviewer conducted data extraction
and analysis. For transparency, all extracted data are
however presented in extensive Additional file 1: supple-
mentary material.
Conclusion
In this assessment, three research clusters were iden-
tified suggesting stratified screening for the general
population, pre-selected high-risk populations and by
using new risk assessment technologies. In 18 studies,
potential biases were identified that might affect the
generalizability of the respective simulation results.
These potential biases consist of not integrating all
relevant phases of care, using utility parameters,
which are based on assumptions, are transferred out
of their original context, are methodologically not
sound, or by using incompatible or inconsistent cost
parameters. Of 18 studies, only three studies did not
show sign of potential bias.
By assessing cost and utility parameter in each phase
of breast cancer care, additional insights into the validity
of these simulation models could be gained. These in-
sights could not be gotten with traditional checklist-
based quality appraisals. This assessment has shown that
a closer look into the cost and utility parameter can help
to identify potential problems.
The challenges for decision analytical modeling,
which derive from the increased complexity from per-
sonalized interventions and the interaction between
risk assessment and surveillance, are not yet ad-
equately met. Future health economic models need to
pay close attention to the integration of all relevant
phases of care. If methodological sound utility param-
eters are not available, sensitivity analyses need to be
applied to reflect the underlying uncertainty regarding
quality of life effects from screening and diagnostic
work up. Cost parameters require close attention in
order to avoid inconsistency or implausible sets for
cost parameters.
Endnotes
1Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)
2Medical Literature Analysis and Retrieval System
(MEDLINE)
3Database of Abstracts of Reviews of Effects (DARE)
4National Health Service Economic Evaluation Data-
base (NHS EED)
5Health Technology Assessment (HTA)
6BRCA1 or BRCA2 stands for the breast cancer sus-
ceptibility gene 1 or 2.
77SNP stands for 7 single nucleotide polymorphism.
8Sensitivity analyses are in the supplementary material
S6.
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